Compare Nuscale Power Corporation (SMR) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuscale Power Corporation vs BIO-TECHNE Corp — how do they compare? Nuscale Power Corporation trades at $8.86 (market cap $2.76B), while BIO-TECHNE Corp trades at $71.63 (market cap $11.16B). The key difference: BIO-TECHNE Corp is far larger — about 4× Nuscale Power Corporation's market cap, and BIO-TECHNE Corp pays a 0.45% dividend while Nuscale Power Corporation pays none. Which is the better fit depends on your goals.
| SMR | TECH | |
|---|---|---|
Market Cap | $2.76B | $11.16B |
Sector | Utilities | Health |
52-Week High | $53.43 | $72.12 |
52-Week Low | $7.64 | $43.31 |
Enterprise Value | $1.87B | $11.24B |
Dividend Yield | — | 0.45% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
